Dyne Therapeutics (DYN) Stock Price, News & Analysis

Company Overview

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells. This strategy aims to address the challenges of systemic delivery and off‐target effects that have limited prior antisense and gene therapy efforts in neuromuscular disorders. By optimizing both the ligand and the cargo, Dyne seeks to achieve sustained target engagement in affected tissues while minimizing exposure elsewhere.

Headquartered in Cambridge, Massachusetts, Dyne Therapeutics operates research and development facilities in the United States and collaborates with partners across Europe and Asia to support global clinical development. The company completed its initial public offering on the Nasdaq market in early 2021, enabling the expansion of its pipeline and investment in manufacturing capabilities for future late‐stage programs.

Dyne’s leadership team brings together executives with extensive experience in biotechnology, pharmaceutical development and clinical operations. The company is governed by a board of directors and scientific advisory members who have led successful drug development programs across multiple therapeutic areas. Dyne continues to engage with patient communities, regulatory agencies and academic institutions to advance its mission of delivering next‐generation therapies for people living with devastating neuromuscular diseases.

Key Stats

• Today's Range: $16.18 to $16.59
• 50-Day Range: $11.24 to $16.53
• 52-Week Range: $6.36 to $35.68
• Volume: 1.73 million shs
• Average Volume: 2.68 million shs
• Market Capitalization: $2.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.07
• Consensus Rating: Moderate Buy

Dyne Therapeutics Stock Analysis - MarketRank™

Dyne Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 369th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 10 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Dyne Therapeutics has a consensus price target of $34.07, representing about 108.0% upside from its current price of $16.38.

Amount of Analyst Coverage

Dyne Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyne Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyne Therapeutics is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyne Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.49% of the outstanding shares of Dyne Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Dyne Therapeutics has recently increased by 16.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyne Therapeutics does not currently pay a dividend.

Dividend Growth

Dyne Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.49% of the outstanding shares of Dyne Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Dyne Therapeutics has recently increased by 16.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.79

News Sentiment

Dyne Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Dyne Therapeutics this week, compared to 8 articles on an average week.

Search Interest

Only 9 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,402.00 in company stock.

Percentage Held by Insiders

14.14% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DYN Stock Analysis - Frequently Asked Questions

How have DYN shares performed this year?

Dyne Therapeutics' stock was trading at $23.56 at the beginning of 2025. Since then, DYN stock has decreased by 30.5% and is now trading at $16.38.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) released its earnings results on Monday, July, 28th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.02.

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' top institutional shareholders include Darwin Wealth Management LLC (0.12%) and Voya Investment Management LLC (0.07%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, John Cox, Oxana Beskrovnaya, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Richard William Scalzo, Dirk Kersten, Johanna Friedl-Naderer and Carlo Incerti.
View institutional ownership trends.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 7/28/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DYN
• Previous Symbol: NYSE:DYN
• CIK: 1818794
• Web: www.dyne-tx.com
• Phone: 781-786-8230
• Fax: 781-786-8866
• Employees: 100
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Dyne Therapeutics: $34.07
• High Price Target: $50.00
• Low Price Target: $9.00
• Potential Upside/Downside: +108.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$317.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.12%
• Return on Assets: -56.75%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 16.83
• Quick Ratio: 16.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.19 per share
• Price / Book: 2.65

Miscellaneous

• Outstanding Shares: 142,264,000
• Free Float: 122,148,000
• Market Cap: $2.33 billion
• Optionable: Optionable
• Beta: 1.09